<?xml version="1.0" encoding="UTF-8"?>
<rootTag>
<Award>
<AwardTitle>STTR Phase I:  A Machine Learning Toolbox to Identify Therapeutics for Rare Genetic Disorders from Phenotypic Screens on Micropattern-Based Organoids</AwardTitle>
<AGENCY>NSF</AGENCY>
<AwardEffectiveDate>02/01/2019</AwardEffectiveDate>
<AwardExpirationDate>10/31/2019</AwardExpirationDate>
<AwardTotalIntnAmount>225000.00</AwardTotalIntnAmount>
<AwardAmount>225000</AwardAmount>
<AwardInstrument>
<Value>Standard Grant</Value>
</AwardInstrument>
<Organization>
<Code>07070000</Code>
<Directorate>
<Abbreviation>ENG</Abbreviation>
<LongName>Directorate For Engineering</LongName>
</Directorate>
<Division>
<Abbreviation>IIP</Abbreviation>
<LongName>Div Of Industrial Innovation &amp; Partnersh</LongName>
</Division>
</Organization>
<ProgramOfficer>
<SignBlockName>Ruth Shuman</SignBlockName>
<PO_EMAI>rshuman@nsf.gov</PO_EMAI>
<PO_PHON>7032922160</PO_PHON>
</ProgramOfficer>
<AbstractNarration>The broader impact/commercial potential of this Small Business Technology Transfer (STTR) Phase I project is to develop a widely applicable, innovative pipeline for drug discovery against rare genetic disorders. While each orphan disease affects a small fraction of individuals, thousands exist, affecting 400 million people world-wide. The challenge to bring therapies to the clinics for diseases that currently have no cure, which is coupled with an expanding market.  Orphan drug sales are expected to reach $262 billion in 2024.  Over the last few years, organoids made from human embryonic stem cells have raised the possibility of understanding the mechanisms leading to a genetic disorder by reconstituting, in vitro, a similar arrangement of the specific cell populations that are implicated in a certain disease. By comparing organoids made from healthy cells to those carrying the associated genetic mutation, drug testing may be performed in vitro to discover new therapeutics. However, this potential has not been harnessed due to technical limitations. In this proposal, as a necessary step towards this goal, the plan is to develop the analytical tools based on machine learning algorithms that will allow the analysis of drug therapeutic potential and toxicity when applied to organoid cultures.&lt;br/&gt;&lt;br/&gt;The intellectual merit of this STTR Phase I project is to develop and validate an unbiased analytical scheme to quantify the results of high-throughput phenotypic screens performed on micropattern organoids. Organoids have the potential to revolutionize the pre-clinical part of the drug discovery pipeline as they provide unbiased endpoints, they are disease relevant, and sensitive to toxicity. However, the use of multi-cellular organization in a high-throughput platform requires analysis of large amounts of information-rich microscopy images. The tools developed in this proposal will allow turning the biological complexity of tissue scale phenotypes into information predictive of the clinical potential of a compound. In the first aim, the goal is to demonstrate that the proposed method allows quantifying compound toxicity. The plan is to calibrate the toolbox against known methods quantifying cell viability, applying known toxic agents and withdrawn drugs. This will constitute a stringent test for the efficiency of the proposed method at quantifying deleterious effects of a compound. Second, the goal is to optimize the algorithm to measure therapeutic potential, using positive controls on micropattern-based organoids modeling Huntington's Disease (HD). The objective is to demonstrate the ability to analyze results of a screening campaign aimed at phenotypic reversal on the HD organoids, and detect hit molecules from a small library of FDA-approved drugs.&lt;br/&gt;&lt;br/&gt;This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.</AbstractNarration>
<MinAmdLetterDate>01/29/2019</MinAmdLetterDate>
<MaxAmdLetterDate>02/22/2019</MaxAmdLetterDate>
<ARRAAmount/>
<TRAN_TYPE>Grant</TRAN_TYPE>
<CFDA_NUM>47.041</CFDA_NUM>
<NSF_PAR_USE_FLAG>1</NSF_PAR_USE_FLAG>
<FUND_AGCY_CODE>4900</FUND_AGCY_CODE>
<AWDG_AGCY_CODE>4900</AWDG_AGCY_CODE>
<AwardID>1843570</AwardID>
<Investigator>
<FirstName>Eric</FirstName>
<LastName>Siggia</LastName>
<PI_MID_INIT>D</PI_MID_INIT>
<PI_SUFX_NAME/>
<PI_FULL_NAME>Eric D Siggia</PI_FULL_NAME>
<EmailAddress>siggiae@rockefeller.edu</EmailAddress>
<PI_PHON>2123278546</PI_PHON>
<NSF_ID>000681018</NSF_ID>
<StartDate>01/29/2019</StartDate>
<EndDate/>
<RoleCode>Co-Principal Investigator</RoleCode>
</Investigator>
<Investigator>
<FirstName>fred</FirstName>
<LastName>etoc</LastName>
<PI_MID_INIT>r</PI_MID_INIT>
<PI_SUFX_NAME/>
<PI_FULL_NAME>fred r etoc</PI_FULL_NAME>
<EmailAddress>fred.etoc@gmail.com</EmailAddress>
<PI_PHON>6467090744</PI_PHON>
<NSF_ID>000781392</NSF_ID>
<StartDate>01/29/2019</StartDate>
<EndDate>02/22/2019</EndDate>
<RoleCode>Former Principal Investigator</RoleCode>
</Investigator>
<Investigator>
<FirstName>Dave</FirstName>
<LastName>Berry</LastName>
<PI_MID_INIT/>
<PI_SUFX_NAME/>
<PI_FULL_NAME>Dave Berry</PI_FULL_NAME>
<EmailAddress>dave@rumiscientific.com</EmailAddress>
<PI_PHON>7576135436</PI_PHON>
<NSF_ID>000797693</NSF_ID>
<StartDate>02/22/2019</StartDate>
<EndDate/>
<RoleCode>Principal Investigator</RoleCode>
</Investigator>
<Institution>
<Name>RUMI SCIENTIFIC, INC.</Name>
<CityName>SAN FRANCISCO</CityName>
<ZipCode>941073007</ZipCode>
<PhoneNumber>3474162688</PhoneNumber>
<StreetAddress>953 INDIANA ST</StreetAddress>
<StreetAddress2/>
<CountryName>United States</CountryName>
<StateName>California</StateName>
<StateCode>CA</StateCode>
<CONGRESSDISTRICT>12</CONGRESSDISTRICT>
<CONGRESS_DISTRICT_ORG>CA12</CONGRESS_DISTRICT_ORG>
<ORG_DUNS_NUM>080617740</ORG_DUNS_NUM>
<ORG_LGL_BUS_NAME>RUMI SCIENTIFIC CALIFORNIA, INC.</ORG_LGL_BUS_NAME>
<ORG_PRNT_DUNS_NUM/>
</Institution>
<Performance_Institution>
<Name><![CDATA[RUMI SCIENTIFIC, INC.]]></Name>
<CityName>san francisco</CityName>
<StateCode>CA</StateCode>
<ZipCode>941073007</ZipCode>
<StreetAddress><![CDATA[953 indiana street, MBC biolabs]]></StreetAddress>
<CountryCode>US</CountryCode>
<CountryName>United States</CountryName>
<StateName>California</StateName>
<CountryFlag>1</CountryFlag>
<CONGRESSDISTRICT>12</CONGRESSDISTRICT>
<CONGRESS_DISTRICT_PERF>CA12</CONGRESS_DISTRICT_PERF>
</Performance_Institution>
<ProgramElement>
<Code>1505</Code>
<Text>STTR Phase I</Text>
</ProgramElement>
<ProgramReference>
<Code>1505</Code>
<Text>STTR PHASE I</Text>
</ProgramReference>
<ProgramReference>
<Code>8038</Code>
<Text>Biotechnology</Text>
</ProgramReference>
<Appropriation>
<Code>0119</Code>
<Name>NSF RESEARCH &amp; RELATED ACTIVIT</Name>
<APP_SYMB_ID>040100</APP_SYMB_ID>
</Appropriation>
<FUND_OBLG>2019~225000</FUND_OBLG>
<POR>
<DRECONTENT><![CDATA[<div class="porColContainerWBG"> <div class="porContentCol"><p>Recent advances in the field of stem cell biology allows the creation, in the laboratory, of physiological models of human organs or &ldquo;organoids&rdquo;. This new technology allows studying human disorders with an unprecedented level of precision. For example, we can grow side by side mini-brain organoids from healthy and pathological genetic backgrounds, image them by microscopy, and pinpoint how mutations associated with neurological disorders affect brain structure and function. In theory, this approach could be used for discovering new therapies by testing large numbers of potential drug to identify hit molecules that reverse the disease signature back to the healthy configuration, thus curing the disease in the petri dish. Those hit molecules will constitute strong therapeutic leads that can then be pushed towards the clinics for curing patients. However, this dream has not been realized yet since there is a lack of analytical tools for analyzing complex microscopy data-sets that are: 1. Very large as they come from the observations of very large numbers of organoids modeling the healthy configuration, the pathological one, and the effect of thousands of individual drug candidate. 2. Complex as each individual tissue is made of many different cell types and arranged in layered geometries, making the identification of relevant metric challenging. 3. Information-rich as we want to extract for each organoid key information related to the disease signature, the healthy configuration, but also the potential positive and adverse effects of the tested drugs.</p> <p>&nbsp;</p> <p>This challenge needs to be tackled by innovative analytical methods, and artificial intelligence is now poised to become the new standard for this task. In this award, we have developed a toolbox for the analysis of drug screening through artificial-intelligence (AI) based algorithms using innovative deep neural networks architecture which can analyze unbiasedly and quickly screening results. In order to calibrate our analysis tools, we have used a model of brain organoids that are grown in confined environment (micropatterning technology) and which model Huntington&rsquo;s Disease (HD), a neurodegenerative disorder for which there is currently no cure. We have first shown that our method can efficiently distinguish healthy and pathological organoids, allowing for the first time to run large complex screens with an unprecedented statistical power. In a second step, we have demonstrated that our tool can quantify precisely the toxicity and adverse effects of potential drugs. This was done by applying defined concentrations of toxic agents to organoids and quantifying the toxic signature by our unbiased algorithm. When comparing with standard methods of toxicity quantification, we were able to show that our algorithm led to an accurate prediction of a compound toxicity. Finally, we have shown that the AI tool can be used to identify new candidate therapeutics for HD by performing and analyzing a screen of 1600 compounds from an approved drugs library.&nbsp;</p> <p>&nbsp;</p> <p>In conclusion, as outcome of this award, we have now in hands a powerful quantification method which is unbiased and can quickly analyze large screening campaigns performed at the level of human tissues and organoids and which can return quantitatively, for each tested compound, two key parameters which are predictive of a drug success in the clinics: drug efficacy and drug toxicity. This new tool unlocks a new possibility for the biotech and pharmaceutical industries to harness the full potential behind recent organoid technologies. We therefore envision this generic toolbox to be of general interest for the future of the drug discovery.</p> <p>&nbsp;</p><br> <p>            Last Modified: 12/02/2019<br>      Modified by: Arjun&nbsp;S&nbsp;Adhikari</p> </div> <div class="porSideCol"></div> </div>]]></DRECONTENT>
<POR_COPY_TXT><![CDATA[ Recent advances in the field of stem cell biology allows the creation, in the laboratory, of physiological models of human organs or "organoids". This new technology allows studying human disorders with an unprecedented level of precision. For example, we can grow side by side mini-brain organoids from healthy and pathological genetic backgrounds, image them by microscopy, and pinpoint how mutations associated with neurological disorders affect brain structure and function. In theory, this approach could be used for discovering new therapies by testing large numbers of potential drug to identify hit molecules that reverse the disease signature back to the healthy configuration, thus curing the disease in the petri dish. Those hit molecules will constitute strong therapeutic leads that can then be pushed towards the clinics for curing patients. However, this dream has not been realized yet since there is a lack of analytical tools for analyzing complex microscopy data-sets that are: 1. Very large as they come from the observations of very large numbers of organoids modeling the healthy configuration, the pathological one, and the effect of thousands of individual drug candidate. 2. Complex as each individual tissue is made of many different cell types and arranged in layered geometries, making the identification of relevant metric challenging. 3. Information-rich as we want to extract for each organoid key information related to the disease signature, the healthy configuration, but also the potential positive and adverse effects of the tested drugs.     This challenge needs to be tackled by innovative analytical methods, and artificial intelligence is now poised to become the new standard for this task. In this award, we have developed a toolbox for the analysis of drug screening through artificial-intelligence (AI) based algorithms using innovative deep neural networks architecture which can analyze unbiasedly and quickly screening results. In order to calibrate our analysis tools, we have used a model of brain organoids that are grown in confined environment (micropatterning technology) and which model Huntingtonâ€™s Disease (HD), a neurodegenerative disorder for which there is currently no cure. We have first shown that our method can efficiently distinguish healthy and pathological organoids, allowing for the first time to run large complex screens with an unprecedented statistical power. In a second step, we have demonstrated that our tool can quantify precisely the toxicity and adverse effects of potential drugs. This was done by applying defined concentrations of toxic agents to organoids and quantifying the toxic signature by our unbiased algorithm. When comparing with standard methods of toxicity quantification, we were able to show that our algorithm led to an accurate prediction of a compound toxicity. Finally, we have shown that the AI tool can be used to identify new candidate therapeutics for HD by performing and analyzing a screen of 1600 compounds from an approved drugs library.      In conclusion, as outcome of this award, we have now in hands a powerful quantification method which is unbiased and can quickly analyze large screening campaigns performed at the level of human tissues and organoids and which can return quantitatively, for each tested compound, two key parameters which are predictive of a drug success in the clinics: drug efficacy and drug toxicity. This new tool unlocks a new possibility for the biotech and pharmaceutical industries to harness the full potential behind recent organoid technologies. We therefore envision this generic toolbox to be of general interest for the future of the drug discovery.          Last Modified: 12/02/2019       Submitted by: Arjun S Adhikari]]></POR_COPY_TXT>
</POR>
</Award>
</rootTag>
